clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT02293109 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P17 | country | United States of America | Q30 |
P582 | end time | 2018-12-01 | |
P4135 | maximum age | 64 | |
P1050 | medical condition | leukemia | Q29496 |
lymphoma | Q208414 | ||
P2899 | minimum age | 18 | |
P1132 | number of participants | 21 | |
P4844 | research intervention | doxorubicin | Q18936 |
cytarabine | Q180983 | ||
(RS)-cyclophosphamide | Q408524 | ||
rituximab | Q412323 | ||
calcium oxalate | Q412399 | ||
methylprednisolone | Q417222 | ||
prednisolone | Q11426176 | ||
leucovorin calcium | Q27077063 | ||
prednisolone acetate | Q27108063 | ||
methylprednisolone hemisuccinate | Q27262132 | ||
prednisolone 21-phosphate | Q27266327 | ||
Caelyx | Q29004943 | ||
P580 | start time | 2015-12-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma |
Search more.